4.6 Article

Canadian Society of Nephrology Commentary on the KDIGO Clinical Practice Guideline for CKD Evaluation and Management

期刊

AMERICAN JOURNAL OF KIDNEY DISEASES
卷 65, 期 2, 页码 177-205

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2014.10.013

关键词

Estimated glomerular filtration rate (eGFR); chronic kidney disease (CKD) staging; albuminuria; kidney disease progression; Kidney Disease: Improving Global Outcomes (KDIGO); clinical practice guideline; Canadian Society of Nephrology (CSN)

资金

  1. Ortho Biotech Inc
  2. GE
  3. Merck Frosst
  4. Sanofi-Aventis
  5. Boehringer Ingelheim
  6. Pfizer
  7. Amgen
  8. Bristol Myers Squibb
  9. Leo Pharma
  10. Astellas
  11. Janssen
  12. Boehringer-Ingelheim
  13. Baxter
  14. Takeda
  15. Abbot

向作者/读者索取更多资源

We congratulate the KDIGO (Kidney Disease: Improving Global Outcomes) work group on their comprehensive work in a broad subject area and agreed with many of the recommendations in their clinical practice guideline on the evaluation and management of chronic kidney disease. We concur with the KDIGO definitions and classification of kidney disease and welcome the addition of albuminuria categories at all levels of glomerular filtration rate (GFR), the terminology of G categories rather than stages to describe level of GFR, the division of former stage 3 into new G categories 3a and 3b, and the addition of the underlying diagnosis. We agree with the use of the heat map to illustrate the relative contributions of low GFR and albuminuria to cardiovascular and renal risk, though we thought that the highest risk category was too broad, including as it does people at disparate levels of risk. We add an albuminuria category A4 for nephrotic-range proteinuria and D and T categories for patients on dialysis or with a functioning renal transplant. We recommend target blood pressure of 140/90 mm Hg regardless of diabetes or proteinuria, and against the combination of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors. We recommend against routine protein restriction. We concur on individualization of hemoglobin A(1c) targets. We do not agree with routine restriction of sodium intake to <2 g/d, instead suggesting reduction of sodium intake in those with high intake (>3.3 g/d). We suggest screening for anemia only when GFR is <30 mL/min/1.73 m(2). We recognize the absence of evidence on appropriate phosphate targets and methods of achieving them and do not agree with suggestions in this area. In drug dosing, we agree with the recommendation of using absolute clearance (ie, milliliters per minute), calculated from the patient's estimated GFR (which is normalized to 1.73 m(2)) and the patient's actual anthropomorphic body surface area. We agree with referral to a nephrologist when GFR is <30 mL/min/ 1.73 m(2) (and for many other scenarios), but suggest urine albumin-creatinine ratio > 60 mg/mmol or proteinuria with protein excretion > 1 g/d as the referral threshold for proteinuria. (C) 2015 by the National Kidney Foundation, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Transplantation

Availability, coverage, and scope of health information systems for kidney care across world countries and regions

Emily J. See, Aminu K. Bello, Adeera Levin, Meaghan Lunney, Mohamed A. Osman, Feng Ye, Gloria E. Ashuntantang, Ezequiel Bellorin-Font, Mohammed Benghanem Gharbi, Sara Davison, Mohammad Ghnaimat, Paul Harden, Htay Htay, Vivekanand Jha, Kamyar Kalantar-Zadeh, Peter G. Kerr, Scott Klarenbach, Csaba P. Kovesdy, Valerie Luyckx, Brendon Neuen, Donal O'Donoghue, Shahrzad Ossareh, Jeffrey Perl, Harun Ur Rashid, Eric Rondeau, Saad Syed, Laura Sola, Irma Tchokhonelidze, Vladimir Tesar, Kriang Tungsanga, Rumeyza Turan Kazancioglu, Angela Yee-Moon Wang, Chih-Wei Yang, Alexander Zemchenkov, Ming-Hui Zhao, Kitty J. Jager, Fergus Caskey, Vlado Perkovic, Kailash K. Jindal, Ikechi G. Okpechi, Marcello Tonelli, John Feehally, David C. Harris, David W. Johnson

Summary: There are significant differences in the coverage and scope of global Health Information Systems (HIS) for kidney disease. KRT registries are available in almost all high-income countries, but rare in low-income countries. Registries for non-dialysis CKD or AKI are also rare. In high-income countries, registries tend to be national, while in low-income countries they often operate at a local or regional level.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2022)

Article Cardiac & Cardiovascular Systems

Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes

Yang Xu, Edouard L. Fu, Marco Trevisan, Tomas Jernberg, Arvid Sjolander, Catherine M. Clase, Juan-Jesus Carrero

Summary: Stopping renin-angiotensin system inhibitors (RASi) after an episode of hyperkalemia may reduce the risk of recurrent hyperkalemia, but is associated with higher risks of death and cardiovascular events.

AMERICAN HEART JOURNAL (2022)

Article Urology & Nephrology

Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study

Silvia J. Leon, Reid Whitlock, Claudio Rigatto, Paul Komenda, Clara Bohm, Ewa Sucha, Sarah E. Bota, Meltem Tuna, David Collister, Manish Sood, Navdeep Tangri

Summary: Discontinuation of RAAS inhibitors is associated with adverse clinical outcomes in patients with CKD, including high mortality, increased risk of cardiovascular events, and initiation of dialysis.

AMERICAN JOURNAL OF KIDNEY DISEASES (2022)

Editorial Material Urology & Nephrology

Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD Understanding and Mitigating the Risks

Murray Epstein, Roberto Pecoits-Filho, Catherine M. Clase, Manish M. Sood, Csaba P. Kovesdy

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Article Urology & Nephrology

Cost of the quanta SC plus hemodialysis system for self-care in the United Kingdom

Thomas W. Ferguson, Gerard D. Harper, John E. Milad, Paul V. J. Komenda

Summary: The development of new personal hemodialysis systems has made dialysis smaller and simpler while maintaining the same effectiveness as conventional systems. Increasing the use of lower-intensity assistance and full self-care dialysis may bring economic benefits to public health payers. The study found that the annual costs of using the SC+ hemodialysis system for self-care dialysis were relatively low in the United Kingdom.

HEMODIALYSIS INTERNATIONAL (2022)

Article Cardiac & Cardiovascular Systems

Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice

Edouard L. Fu, Catherine M. Clase, Roemer J. Janse, Bengt Lindholm, Friedo W. Dekker, Meg J. Jardine, Juan-Jesus Carrero

Summary: This study investigates the comparative effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA) on cardiovascular outcomes in routine clinical practice. The study finds no significant differences in major adverse cardiovascular events between the two therapies, but the use of SGLT2i is associated with a small increase in the risk of ischemic stroke.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2022)

Article Urology & Nephrology

GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes

Yang Xu, Edouard L. Fu, Catherine M. Clase, Faizan Mazhar, Meg J. Jardine, Juan J. Carrero

Summary: In this study, it was found that glucagon-like peptide-1 receptor agonists (GLP1RA) were associated with a lower risk of kidney outcomes compared to dipeptidyl peptidase-4 inhibitors (DPP4i). The reductions in both kidney outcomes and major adverse cardiovascular events (MACE) were similar in magnitude to those reported in large cardiovascular outcome trials.

KIDNEY INTERNATIONAL (2022)

Review Urology & Nephrology

Epidemiology of haemodialysis outcomes

Aminu K. Bello, Ikechi G. Okpechi, Mohamed A. Osman, Yeoungjee Cho, Htay Htay, Vivekanand Jha, Marina Wainstein, David W. Johnson

Summary: Haemodialysis is the most common form of kidney replacement therapy worldwide, but its availability, accessibility, cost, and outcomes vary across regions. Cardiovascular disease is the major cause of morbidity and mortality in haemodialysis patients. Understanding the epidemiology of haemodialysis outcomes and finding strategies for improvement are crucial.

NATURE REVIEWS NEPHROLOGY (2022)

Editorial Material Urology & Nephrology

Conflicts of Interest and the Trustworthiness of Clinical Practice Guidelines

Anna Mathew, Catherine M. Clase

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Article Multidisciplinary Sciences

Fitted filtration efficiency and breathability of 2-ply cotton masks: Identification of cotton consumer categories acceptable for home-made cloth mask construction

Ken G. Drouillard, Amanda Tomkins, Sharon Lackie, Scott Laengert, Allison Baker, Catherine M. Clase, Charles F. De Lannoy, Dora Cavallo-Medved, Lisa A. Porter, Rebecca S. Rudman

Summary: The objective of this study was to assess commercially-available cotton fabrics for the construction of cloth masks. The study found that certain cotton fabrics can produce breathable masks with filtration efficiencies comparable to medical masks.

PLOS ONE (2022)

Article Medicine, General & Internal

Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial

Paris J. Baptiste, Angel Y. S. Wong, Anna Schultze, Marianne Cunnington, Johannes F. E. Mann, Catherine Clase, Clemence Leyrat, Laurie A. Tomlinson, Kevin Wing

Summary: Cardiovascular disease is a leading cause of death globally. Clinical trial results may not be fully applicable to underrepresented groups. This study aims to replicate previous clinical trial results using real-world data and evaluate treatment effects and risks in excluded populations.

BMJ OPEN (2022)

Article Urology & Nephrology

Sex Differences in the Recognition, Monitoring, and Management of CKD in Health Care: An Observational Cohort Study

Oskar Swartling, Yuanhang Yang, Catherine M. Clase, Edouard L. Fu, Manfred Hecking, Sebastian Hoedlmoser, Ylva Trolle-Lagerros, Marie Evans, Juan J. Carrero

Summary: This study evaluated the sex differences in CKD patients and found that the disparities may be explained by differences in healthcare.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Editorial Material Urology & Nephrology

Telehealth and Management Support for Hypertension in CKD: Time to Raise the Bar

Ikechi G. Okpechi, Aminu K. Bello

KIDNEY360 (2023)

Article Urology & Nephrology

Magnitude of the Potential Screening Gap for Fabry Disease in Manitoba: A Population-Based Retrospective Cohort Study

Reid H. Whitlock, Mohammad Nour-Mohammadi, Sarah Curtis, Paul Komenda, Clara Bohm, David Collister, Navdeep Tangri, Claudio Rigatto

Summary: This study used administrative health databases to identify patients at high risk of Fabry disease and found that 1364 high-risk patients had not been tested. Administrative health databases can assist in identifying high-risk populations and further design screening programs for Fabry disease.

CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE (2023)

Review Urology & Nephrology

Patient Navigators for CKD and Kidney Failure: A Systematic Review

Ali Taha, Yasmin Iman, Jay Hingwala, Nicole Askin, Priyanka Mysore, Claudio Rigatto, Clara Bohm, Paul Komenda, Navdeep Tangri, David Collister

Summary: This article conducted a systematic review on patient navigator programs in kidney disease and found that navigators can improve some health outcomes for patients with chronic kidney disease, but there is heterogeneity in their structure and function.

KIDNEY MEDICINE (2022)

暂无数据